Effects of nimodipine on glutamate transporter expression of SAH model rats

doi:10.3877/cma.j.issn.2095-9141.2017.04.009

Abstract

Abstract:

Objective

To investigate the effects of Nimodipine on the expression of glutamate transporter in the brain stem of subarachnoid hemorrhage (SAH) rats.

Methods

Fifty-four Wistar rats were randomly divided into control group (n=6), SAH group (n=24) and SAH-Nimodipine group (n=24). SAH model was established by injecting blood twice. The level of glutamate transporter (EAATs) mRNA and the maximal blood flow velocity of basilar artery in rats were detected by injection of Nimodipine.

Results

The Vba of SAH group was significantly higher than that of control group at 1, 7 and 14 d (P<0.05). The Vba of SAH-Nimodipine group was significantly higher than that of control group at 1 and 7 d (P<0.05). The Vba of 1, 7 and 14 d were significantly lower than those of the control group (P<0.05). EAAT-1/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of SAH group was significantly lower than that of control group at 1 d (P<0.05), and 21 d significantly higher than that of control group (P<0.05). The EAAT-1/GAPDH of SAH-Nimodipine group was significantly higher than that of the control group at 4 time points (P<0.05); the 1, 7 and 14 d were significantly higher than SAH group (P<0.05). The EAAT-2/GAPDH of SAH group was significantly lower than that of the control group at 1 and 7 d (P<0.05), and the EAAT-2/GAPDH of SAH group was significantly higher than that of SAH group at 14 d and 21 d after SAH-Nimodipine treatment (P<0.05). The EAAT-3/GAPDH of SAH group was significantly lower than that of the control group at 1 and 7 d (P<0.05). The EAAT-3/GAPDH of SAH group was significantly higher than that of SAH group at 1 and 7 d after SAH-nimodipine treatment(P<0.05).

Conclusion

Nimodipine can effectively increase the expression of EAATs, thereby relieving cerebral vasospasm, treatment of SAH.

Key words: Nimodipine, Subarachnoid hemorrhage, Excitatory amino acid transporters

Lin Wang, Tao Wang, Yingchun Liang, Fangbo Ning, Fangfang Zhao, Xinna Zhang, Lei Zhang. Effects of nimodipine on glutamate transporter expression of SAH model rats[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2017, 03(04): 226-229.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2017.04.009

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2017/V03/I04/226

Figures/Tables 4

References 15

[1]	夏程，曲方，陈会生,等.自发性脑凸面蛛网膜下腔出血临床及影像学诊断分析:附五例典型病例报道[J].中国全科医学, 2014, 17(24): 2840-2843.
[2]	Tso MK, Macdonald RL. Subarachnoid hemorrhage: a review of experimental studies on the microcirculation and the neurovascular unit[J]. Transl Stroke Res, 2014, 5(2): 174-189.
[3]	Zaric N, Milovanovic-Kovacevic N, Savic M, et al. Effectiveness OF TCCS in diagnosis of middle cerebral artery spasm resulting SAH-Compared to DSA as reference standard[J]. Int J Stroke, 2014, 14(9): 60-61.
[4]	叶蓓，陈建珍，张立光,等. Humanin对谷氨酸诱导大鼠脊髓神经元兴奋性损伤的影响[J].山东医药, 2014, 14(22): 26-28.
[5]	Jensen AA, Fahlke C, Bjørn-Yoshimoto WE, et al. Excitatory amino acid transporters: recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities[J]. Curr Opin Pharmacol, 2015, 20: 116-123.
[6]	Hänggi D, Etminan N, Macdonald RL, et al. NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage[J]. Neurocrit Care, 2015, 23(2): 274-284.
[7]	Mackenzie M, Gorman SK, Doucette S, et al. Incidence of and factors associated with manipulation of nimodipine dosage in patients with aneurysmal subarachnoid hemorrhage[J]. Can J Hosp Pharm, 2014, 67(5): 358-365.
[8]	孟晗，田新华，王志刚,等.两种制作蛛网膜下腔出血大鼠模型方法及效果比较[J].中华神经医学杂志, 2014, 13(7): 677-681.
[9]	Bogason ET, Anderson B, Brandmeir NJ, et al. The epidemiology of admissions of nontraumatic subarachnoid hemorrhage in the United States[J]. Neurosurgery, 2014, 74(2):227-229.
[10]	Suarez JI. Diagnosis and Management of Subarachnoid Hemorrhage[J]. Continuum (Minneap Minn), 2015, 21(5): 1263-1287.
[11]	中国脑血管病杂志编辑部.脑缺血预适应通过上调胶质细胞谷氨酸转运体-1的摄取活性降低谷氨酸的兴奋毒性[J].中国脑血管病杂志, 2014, 14(6): 336.
[12]	Divito CB, Underhill SM. Excitatory amino acid transporters: roles in glutamatergic neurotransmission[J]. Neurochem Int, 2014, 73: 172-180.
[13]	张淑娣，张晓娟.尼莫地平在神经科的临床应用[J].中国临床神经外科杂志, 2016, 21(11): 727-728.
[14]	张哲英，唐勇，甄玲玲,等.尼莫地平治疗外伤性蛛网膜下腔出血疗效的系统评价[J].重庆医学, 2014, 43(18): 2291-2293.
[15]	Sandow N, Diesing D, Sarrafzadeh A, et al. Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage[J]. Neurocritical Care, 2016, 25(1): 29-39.

组别	只数	SAH前	SAH后
组别	只数	SAH前	1d	7 d	14 d	21 d
对照组	6	25.42±4.26	25.67±3.56	26.36±2.86	25.73±3.75	24.76±4.53
SAH组	6	25.19±4.86	40.35±2.64^a1	55.85±3.64^a2	34.73±4.68^a3	25.67±6.76
SAH?尼莫地平组	6	24.35±4.64	34.35±4.76^a4b1	42.15±4.25^a5b2	26.85±5.35^b3	24.74±3.38

组别	只数	SAH前	SAH后
组别	只数	SAH前	1d	7 d	14 d	21 d
对照组	6	25.42±4.26	25.67±3.56	26.36±2.86	25.73±3.75	24.76±4.53
SAH组	6	25.19±4.86	40.35±2.64^a1	55.85±3.64^a2	34.73±4.68^a3	25.67±6.76
SAH?尼莫地平组	6	24.35±4.64	34.35±4.76^a4b1	42.15±4.25^a5b2	26.85±5.35^b3	24.74±3.38

组别	只数	1d	7 d	14 d	21 d
对照组	6	0.44±0.03	?	?	?
SAH组	6	0.23±0.02^a1	0.38±0.04	0.63±0.08^a2	1.20±0.11^a3
SAH?尼莫地平组	6	0.99±0.12^a4b1	0.97±0.14^a5b2	1.02±0.14^a6b3	2.14±0.12^a7

组别	只数	1d	7 d	14 d	21 d
对照组	6	0.44±0.03	?	?	?
SAH组	6	0.23±0.02^a1	0.38±0.04	0.63±0.08^a2	1.20±0.11^a3
SAH?尼莫地平组	6	0.99±0.12^a4b1	0.97±0.14^a5b2	1.02±0.14^a6b3	2.14±0.12^a7

组别	只数	1 d	7d	14 d	21 d
对照组	6	0.26±0.02	?	?	?
SAH组	6	0.11±0.01^a1	0.14±0.02^a2	0.25±0.03	0.24±0.03
SAH?尼莫地平组	6	0.27±0.03^b1	0.25±0.05^b2	0.39±0.08^a3b3	0.40±0.07^a4b4

Please choose a citation manager

Content to export